Patents
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
05/2005
05/10/2005US6890744 Nucleotide sequences coding transcription factor for use in generation of lysine for use in animal nutrients the foods
05/10/2005US6890743 Geminin and Orc3N inhibit replication of herpesviruses, papillomaviruses, and polyomaviruses
05/10/2005US6890738 Prolactin antagonists and uses thereof
05/10/2005US6890737 For prognosing/monitoring efficiency of treatment of chronic hepatitis/natural disease; genetic engineering
05/10/2005US6890735 TSG-like gene
05/10/2005US6890734 Nucleic acids encoding a cytokine receptor complex
05/10/2005US6890733 MEKK1 (serine threonine kinases)-interacting FHA (forkhead associated domain) protein 1 (M1F1)
05/10/2005US6890731 For drug screeing/therapy of diseases; bacteriophages
05/10/2005US6890730 For enhanced biomass production/secretion; fusion proteins/ membranes
05/10/2005US6890725 Proteins; antiproliferative agent; autoimmune disease; antiinflammatory agents
05/10/2005US6890720 Antigens derived from filaggrin and their use for diagnosing rheumatoid polyarthritis
05/10/2005US6890717 For diagnostics/screening assays/hybridization probes/primers/therapy for osteoporosis/periodontal disease
05/10/2005US6890713 For improving the effectiveness of chemotherapy; drug screening/design
05/10/2005US6890710 For treating influenza infections in vivo; fusion proteins; solid phase synthesis
05/10/2005US6890709 For induction of S-phase/oncogenicity/transcription/apoptosis in cells
05/10/2005US6890565 Extracting coagulant protein derivatives from seeds of trees within the family Moringaceae especially those of Moringa oleifera Lam (syns Moringa pterygosperma Gaertn.)
05/10/2005US6890542 The use of a live mutant Leishmania in the preparation of a vaccine and to vaccine formulations for use in immunising mammals, such as dogs and/or humans. The mutant Leishmania comprises at least one defective cysteine proteinase gene.
05/10/2005US6890539 Peptide encoded by gene identified herein as pho2-2, obtainable from Group B Streptococcus, or a homologue or a functional fragment thereof; neonatal infections, urinary tract infections
05/10/2005US6890537 Antigrowth agents; microbiocides, bactericides
05/10/2005US6890536 Microsporidian polar tube proteins, nucleic acids coding for these proteins and their applications
05/10/2005US6890535 Pharmaceutical compositions and methods for treatment of amyloid diseases
05/10/2005US6890534 Aiolos genes and polypeptides of the present invention are useful for studying, diagnosing and/or treating diseases associated with unwanted cell proliferation, e.g., leukemias or lymphomas
05/10/2005US6890531 Neuronal growth factor galectin-1
05/10/2005US6890528 Cells for the production of helper dependent adenoviral vectors
05/10/2005US6890518 Compositions of chemically modified insulin
05/10/2005US6890516 Identifying a substance capable of affecting long term memory in an animal comprising the determination that said substance alters activator homodimer, activator-repressor heterodimer and/ or repressor homodimer formation from normal
05/10/2005US6890515 Non-invasive localization of a light-emitting conjugate in a mammal
05/10/2005US6890512 Methods of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby
05/10/2005CA2330935C A mutant human hepatitis b viral strain and uses thereof
05/10/2005CA2123579C Recombinant multivalent m protein vaccine
05/10/2005CA2116559C Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
05/10/2005CA2116192C Highly concentrated tcf pharmaceutical preparations
05/10/2005CA1341482C Process for preparing fragments of aids-associated retroviruses
05/06/2005WO2005040821A1 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 18 (gpr18)
05/06/2005WO2005040799A1 Artificial antibody comprising complementary peptide
05/06/2005WO2005040426A1 Molecular marker associated with cmv resistance and use thereof
05/06/2005WO2005040418A2 Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt
05/06/2005WO2005040384A1 Minimal dna sequence acting as a chromatin insulator and its use in protein expression
05/06/2005WO2005040383A1 B lymphoid lineage specific promoter sequences and pharmaceutical compositions containing the same
05/06/2005WO2005040380A1 Rodent immune response regulatory proteins
05/06/2005WO2005040375A1 A fungal immuromodulatory protein produced by microorganisme and uses thereof
05/06/2005WO2005040368A2 Crystals of an aurora-a tpx2 complex, tpx2 binding site of aurora-a, aurora-a ligands and their use
05/06/2005WO2005040365A1 Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein
05/06/2005WO2005040359A1 Vaccine for periodontal disease
05/06/2005WO2005040356A2 Mutant p53 protein and uses thereof
05/06/2005WO2005040353A2 Immunogenic compostion and method of developing a vaccine based on psoralen inactivated hiv
05/06/2005WO2005040352A2 Immunogenic composition and method of developing a vaccine based on factor h binding sites
05/06/2005WO2005040349A2 Immunogenic composition and method of developing a vaccine based on cyclophilin a binding site
05/06/2005WO2005040344A2 Generation of stabilized proteins by combinatorial consensus mutagenesis
05/06/2005WO2005040341A2 Human prostaglandin ep4 receptor variants and methods of using same
05/06/2005WO2005040335A2 A novel mutated nerve growth factor beta gene, proteins encoded thereby, and products and methods related thereto
05/06/2005WO2005040333A2 Ligand-pseudoreceptor system for generation of adenoviral vectors with altered tropism
05/06/2005WO2005040229A2 Ldl receptor class a and egf domain monomers and multimers
05/06/2005WO2005040218A1 METHOD FOR PREPARING COMPOSITE IgY SPECIFIC AGAINST PERIODONTAL DISEASE AND COMPOSITE PREPARATION THEREOF
05/06/2005WO2005040215A2 Ovomucoid promoters and mehtods of use
05/06/2005WO2005040214A1 Virally-safe factor viii with a low content of higher multimers
05/06/2005WO2005040213A1 MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
05/06/2005WO2005040212A2 Orthogonal gene switches
05/06/2005WO2005040210A2 Novel cxcl8 antagonists
05/06/2005WO2005040209A1 Human chemokine hcc-1 polypeptides to improve stem cell transplantation
05/06/2005WO2005040208A2 Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use
05/06/2005WO2005040207A1 Tyrosine phosphorylation of cdk inhibitor proteins of the cip/kip family
05/06/2005WO2005040206A1 Glurp-msp3 fusion protein, immunogenic compositions and malarial vaccines containing it
05/06/2005WO2005040205A1 Peptides with anti-obesity activity and other related uses
05/06/2005WO2005040204A1 A tumor-inhibiting protein and the use thereof
05/06/2005WO2005040203A2 Msp-3-like family of genes
05/06/2005WO2005040202A2 Stabilized alpha-helical peptides
05/06/2005WO2005040201A1 Human cathelicidin antimicrobial peptides
05/06/2005WO2005040200A1 Protein expression
05/06/2005WO2005040199A1 A bidentate motif and methods of use
05/06/2005WO2005040198A1 A binding motif and methods of regulating cell function
05/06/2005WO2005040197A1 Compositions, methods and kits for biarsenical fluorophore labeling
05/06/2005WO2005040195A2 Formulation of exendins
05/06/2005WO2005040194A2 Methods and compositions for pdgf-c activation and inhibition
05/06/2005WO2005040193A2 Synthetic peptides that cause f-actin bundling and block actin depolymerization
05/06/2005WO2005040192A2 Human cathelicidin antimicrobial peptides
05/06/2005WO2005040191A2 Ccn1 compositions and methods
05/06/2005WO2005039644A1 Method of transferring soluble interferon ϝ receptor gene and composition for preventing or treating arteriosclerosis
05/06/2005WO2005039643A2 In vivo gene therapy of parkinson's disease
05/06/2005WO2005039633A1 Agent for treating leishmania infections
05/06/2005WO2005039632A1 Colorectal cancer antigen
05/06/2005WO2005039631A1 Vaccines containing the hiv tat protein as an adjuvant for the enhancement of cytotoxic t-cell responses
05/06/2005WO2005039618A1 p185neu-ENCODING DNA AND THERAPEUTICAL USES THEREOF
05/06/2005WO2005039616A1 Angiogenic peptides and uses thereof
05/06/2005WO2005039613A1 Lim2 inhibitor of lm02
05/06/2005WO2005039607A1 The use of balloonfish collagen i extractive in medical care and the preparative method of it
05/06/2005WO2005039501A2 Immunogenic composition and method of developing a vaccine based on fusion protein
05/06/2005WO2005030240A3 Vege-cor vege-d materials and methods for stimulation of neural stem cells
05/06/2005WO2005023834A3 Peptides and compounds that bind to thrombopoietin receptors
05/06/2005WO2005019454A8 Novel rat calcium channel subunits and related probes, cell lines and methods
05/06/2005WO2005017161A3 Chimeric peptides for the regulation of gtpases
05/06/2005WO2005014622A3 Ra antigenic peptides
05/06/2005WO2005005467A3 Novel immune booster compound comprising an ef adenoviral sequence
05/06/2005WO2005004592A3 Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications
05/06/2005WO2005000888A3 NOVEL β-ACTIN AND RPS21 PROMOTERS AND USES THEREOF
05/06/2005WO2004112727A3 Aav virions with decreased immunoreactivity and uses therefor
05/06/2005WO2004097425A3 Method of selecting chemokine antagonists and agonists
05/06/2005WO2004094622A3 Extracellular messengers
05/06/2005WO2004093830A3 Model for neurodegenerative disorders
05/06/2005WO2004093785A3 Rhesus monkey bombesin receptor subtype-3 (brs-3), nucleotides encoding same, and uses thereof